BAQSIMITM is indicated for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.
BAQSIMI has not been studied in pediatric patients below the age of 4.
Limited clinical trial experience has not identified difference in responses between elderly (≥65 years of age) and younger patients.
- Hypersensitivity to glucagon or to any ingredient in the formulation or container
Lack of response: BAQSIMI should be given only in patients where impaired consciousness precludes oral carbohydrates. After intranasal administration of BAQSIMI, the patient will normally respond within 15 minutes. If the patient does not respond within 15 minutes, intravenous glucose must be administered as soon as possible.
States of starvation, adrenal insufficiency or chronic hypoglycemia: because glucagon is of little or no help in these cases, intravenous glucose should be used for the treatment of hypoglycemia in these conditions.
- Cardiovascular effects
- Driving and operating machinery
- Sensitivity and resistance to glucagon
- Pregnant women
- Pediatrics (<4 years of age)
- Geriatrics (>65 years of age)
- Use in patients with Type 2 diabetes taking sulfonylureas
- Use with alcohol
- Monitoring and laboratory tests
Consult the product monograph at http://pi.lilly.com/ca/baqsimi-ca-pm.pdf for additional important information relating to warnings and precautions, adverse reactions, drug interactions and dosing information which have not been discussed in this piece. The product monograph is also available by calling 1-888-545-5972.References: 1. Eli Lilly Canada Inc. Data on file. 2. BAQSIMI Product Monograph. Eli Lilly and Company. September 25, 2019.